EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform

Ying Fang, Yuning Chen, Yan-Ruide Li

Stem Cell Reports · 2025-07 · 20 (7) · 102515

DOI: 10.1016/j.stemcr.2025.102515 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Stem Cell Reports, 2025-07. Verfasst von Ying Fang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengi…. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Cell Engineering. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of California Los Angeles.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past five years, allogeneic off-the-shelf CAR-engineered cell therapies have advanced rapidly. By bypassing the individualized manufacturing, high cost, and eligibility constraints of autologous products, allogeneic platforms, especially those derived from induced pluripotent stem cells (iPSCs), promise broader, faster access for cancer patients. This perspective reviews recent preclinical and clinical milestones, outlining genetic designs, scalable production workflows, and early-phase trial outcomes. We assess safety profiles, antitumor activity, and in vivo persistence, spotlighting innovations like T cell receptor alpha constant (TRAC) knockout, human leukocyte antigen (HLA) camouflage, and interleukin (IL)-15 armoring. Finally, we identify emerging trends and challenges that will shape the future development of allogeneic iPSC-derived CAR therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induced Pluripotent Stem CellsReceptors, Chimeric AntigenImmunotherapy, AdoptiveCell EngineeringAllogeneic CellsHumansAnimalsNeoplasms

Stichwörter der Autor:innen

CARCRISPRallogeneic cell therapycancerchimeric antigen receptorclinical trialsiPSCimmunotherapyinduced pluripotent stem cell

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095,…

Förderung

  • University of California Los Angeles

Zitieren

APA

Fang, Y., Chen, Y., & Li, Y. R. (2025). Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform. Stem Cell Reports, 20(7), 102515. https://doi.org/10.1016/j.stemcr.2025.102515

Vancouver

Fang Y, Chen Y, Li YR. Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform. Stem Cell Reports. 2025;20(7):102515. doi:10.1016/j.stemcr.2025.102515

BibTeX
@article{Fang2025,
  author = {Fang, Ying and Chen, Yuning and Li, Yan-Ruide},
  title = {Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform},
  journal = {Stem Cell Reports},
  year = {2025},
  volume = {20},
  number = {7},
  pages = {102515},
  doi = {10.1016/j.stemcr.2025.102515}
}
Kostenlos starten →